{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T10:13:16Z","timestamp":1783764796688,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,11]]},"DOI":"10.7759\/cureus.112448","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T09:50:29Z","timestamp":1783763429000},"source":"Crossref","is-referenced-by-count":0,"title":["Longitudinal Hepatic and Metabolic Trajectories Following Dolutegravir Initiation in Antiretroviral Therapy (ART)-Na\u00efve People Living With HIV: A Prospective Cohort Study From South India"],"prefix":"10.7759","author":[{"given":"Savitha A","family":"Sebastian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumithra","family":"Selvam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100573","article-title":"Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: a systematic literature review and network meta-analysis","volume":"28","author":"Kanters S","year":"2020","unstructured":"Kanters S, Vitoria M, Zoratti M, et al.. Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: a systematic literature review and network meta-analysis. EClinicalMedicine. 2020, 28:100573. 10.1016\/j.eclinm.2020.100573","journal-title":"EClinicalMedicine"},{"key":"ref2","unstructured":"Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring. recommendations for a public health approach. (2021). Accessed: June 14, 2026: https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/a4c03ed9-5446-4958-a26f-10e505c2679c\/content."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1310\/hct1505-199","article-title":"Dolutegravir: clinical and laboratory safety in integrase inhibitor-naive patients","volume":"15","author":"Curtis L","year":"2014","unstructured":"Curtis L, Nichols G, Stainsby C, et al.. Dolutegravir: clinical and laboratory safety in integrase inhibitor-naive patients. HIV Clin Trials. 2014, 15:199-208. 10.1310\/hct1505-199","journal-title":"HIV Clin Trials"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.36349\/easjms.2026.v08i02.004","article-title":"Hepatotoxicity in dolutegravir vs non - dolutegravir antiretroviral regimen: narrative review","volume":"8","author":"Kinoti N","year":"2026","unstructured":"Kinoti N, Suresh P, Wafula N, Volente DO, Makumi D. Hepatotoxicity in dolutegravir vs non - dolutegravir antiretroviral regimen: narrative review. East African Scholars J Med Surg. 2026, 8:60-7. 10.36349\/easjms.2026.v08i02.004","journal-title":"East African Scholars J Med Surg"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx122","article-title":"Abacavir\/dolutegravir\/lamivudine (Triumeq)-induced liver toxicity in a human immunodeficiency virus-infected patient","volume":"4","author":"Christensen ES","year":"2017","unstructured":"Christensen ES, Jain R, Roxby AC. Abacavir\/dolutegravir\/lamivudine (Triumeq)-induced liver toxicity in a human immunodeficiency virus-infected patient. Open Forum Infect Dis. 2017, 4:ofx122. 10.1093\/ofid\/ofx122","journal-title":"Open Forum Infect Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1177\/0956462417734099","article-title":"Dolutegravir-induced liver injury leading to sub-acute liver failure requiring transplantation: a case report and review of literature","volume":"29","author":"Wang B","year":"2018","unstructured":"Wang B, Abbott L, Childs K, et al.. Dolutegravir-induced liver injury leading to sub-acute liver failure requiring transplantation: a case report and review of literature. Int J STD AIDS. 2018, 29:414-7. 10.1177\/0956462417734099","journal-title":"Int J STD AIDS"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1625601","article-title":"Post-marketing safety concerns with dolutegravir: a pharmacovigilance study based on the FDA adverse event reporting system database","volume":"16","author":"Su J","year":"2025","unstructured":"Su J, He L, Wang M. Post-marketing safety concerns with dolutegravir: a pharmacovigilance study based on the FDA adverse event reporting system database. Front Pharmacol. 2025, 16:1625601. 10.3389\/fphar.2025.1625601","journal-title":"Front Pharmacol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/20503121241260613","article-title":"A review of dolutegravir-associated weight gain and secondary metabolic comorbidities","volume":"12","author":"Jemal M","year":"2024","unstructured":"Jemal M. A review of dolutegravir-associated weight gain and secondary metabolic comorbidities. SAGE Open Med. 2024, 12:20503121241260613. 10.1177\/20503121241260613","journal-title":"SAGE Open Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz407","article-title":"Greater weight gain in treatment-na\u00efve persons starting dolutegravir-based antiretroviral therapy","volume":"70","author":"Bourgi K","year":"2020","unstructured":"Bourgi K, Rebeiro PF, Turner M, et al.. Greater weight gain in treatment-na\u00efve persons starting dolutegravir-based antiretroviral therapy. Clin Infect Dis. 2020, 70:1267-74. 10.1093\/cid\/ciz407","journal-title":"Clin Infect Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s41043-024-00695-0","article-title":"Incidence of type 2 diabetes mellitus in persons living with HIV initiated on dolutegravir-based antiretroviral regimen in Ghana: an observational longitudinal study","volume":"43","author":"Lartey M","year":"2024","unstructured":"Lartey M, Kenu E, Ganu V, et al.. Incidence of type 2 diabetes mellitus in persons living with HIV initiated on dolutegravir-based antiretroviral regimen in Ghana: an observational longitudinal study. J Health Popul Nutr. 2024, 43:199. 10.1186\/s41043-024-00695-0","journal-title":"J Health Popul Nutr"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002811","article-title":"Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents","volume":"35","year":"2021","unstructured":"Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents. AIDS. 2021, 35.869-82. 10.1097\/QAD.0000000000002811","journal-title":"AIDS"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2174\/011570162X264021231108010324","article-title":"A phase-IV non-interventional study to assess virological effectiveness, safety, and tolerability of DTG-based antiretroviral therapy in HIV-1 infected Indian persons living with HIV","volume":"22","author":"Ashta KK","year":"2024","unstructured":"Ashta KK, Arora S, Khanna R, Raman N, Anilkumar A, Mohan C. A phase-IV non-interventional study to assess virological effectiveness, safety, and tolerability of DTG-based antiretroviral therapy in HIV-1 infected Indian persons living with HIV. Curr HIV Res. 2024, 22:31-46. 10.2174\/011570162X264021231108010324","journal-title":"Curr HIV Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1177\/09564624251352064","article-title":"Long-term efficacy and safety of fixed-dose dolutegravir-lamivudine in people with HIV: a retrospective study from India","volume":"36","author":"Kulkarni V","year":"2025","unstructured":"Kulkarni V, Parchure R, Gundu S, Darak T, Kurkute K, Kulkarni K. Long-term efficacy and safety of fixed-dose dolutegravir-lamivudine in people with HIV: a retrospective study from India. Int J STD AIDS. 2025, 36:930-8. 10.1177\/09564624251352064","journal-title":"Int J STD AIDS"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.62522","article-title":"Clinical profile and adverse effects of dolutegravir treatment in HIV-positive patients: a prospective observational study","volume":"16","author":"Joshi K","year":"2024","unstructured":"Joshi K, Shinde S, Karatela S, Mulkalwar A. Clinical profile and adverse effects of dolutegravir treatment in HIV-positive patients: a prospective observational study. Cureus. 2024, 16:e62522. 10.7759\/cureus.62522","journal-title":"Cureus"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1089\/AID.2022.0167","article-title":"Effectiveness, weight changes, and metabolic outcomes on switch to generic dolutegravir\/lamivudine among people with HIV in western India: an observational study","volume":"40","author":"Pujari S","year":"2024","unstructured":"Pujari S, Gaikwad S, Panchawagh S, et al.. Effectiveness, weight changes, and metabolic outcomes on switch to generic dolutegravir\/lamivudine among people with HIV in western India: an observational study. AIDS Res Hum Retroviruses. 2024, 40:204-15. 10.1089\/AID.2022.0167","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref16","unstructured":"Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events, Corrected Version 2.1. (2017). Accessed. June 14, 2026: https:\/\/rsc.niaid.nih.gov\/sites\/default\/files\/daidsgradingcorrectedv21.pdf."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.4102\/sajhivmed.v18i1.776","article-title":"Adult antiretroviral therapy guidelines 2017","volume":"18","author":"Meintjes G","year":"2017","unstructured":"Meintjes G, Moorhouse MA, Carmona S, et al.. Adult antiretroviral therapy guidelines 2017. South Afr J HIV Med. 2017, 18:776. 10.4102\/sajhivmed.v18i1.776","journal-title":"South Afr J HIV Med"},{"key":"ref18","unstructured":"National guidelines for HIV care and treatment 2021. (2021). Accessed. June 14, 2026: https:\/\/www.differentiatedservicedelivery.org\/wp-content\/uploads\/National_Guidelines_for_HIV_Care_and_Treatment_2021.pdf."},{"key":"ref19","unstructured":"The Asia-Pacific perspective. redefining obesity and its treatment. (2000). Accessed: June 14, 2026: https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/53228dc6-9520-421b-b5a2-f826967090cb\/content."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-0403","article-title":"Random capillary blood glucose cut points for diabetes and pre-diabetes derived from community-based opportunistic screening in India","volume":"32","author":"Somannavar S","year":"2009","unstructured":"Somannavar S, Ganesan A, Deepa M, Datta M, Mohan V. Random capillary blood glucose cut points for diabetes and pre-diabetes derived from community-based opportunistic screening in India. Diabetes Care. 2009, 32:641-3. 10.2337\/dc08-0403","journal-title":"Diabetes Care"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-S002","article-title":"Diagnosis and classification of diabetes: standards of care in diabetes\u20142024","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","unstructured":"American Diabetes Association Professional Practice Committee. Diagnosis and classification of diabetes: standards of care in diabetes\u20142024. Diabetes Care. 2024, 47:S20-42. 10.2337\/dc24-S002","journal-title":"Diabetes Care"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1177\/2042098620976953","article-title":"Antiretroviral therapy and liver disorders in the OPERA(\u00ae) cohort","volume":"11","author":"Wohlfeiler M","year":"2020","unstructured":"Wohlfeiler M, Mounzer K, Brunet L, et al.. Antiretroviral therapy and liver disorders in the OPERA(\u00ae) cohort. Ther Adv Drug Saf. 2020, 11:2042098620976953. 10.1177\/2042098620976953","journal-title":"Ther Adv Drug Saf"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0105-0","article-title":"Drug-induced liver injury","volume":"5","author":"Andrade RJ","year":"2019","unstructured":"Andrade RJ, Chalasani N, Bj\u00f6rnsson ES, et al.. Drug-induced liver injury. Nat Rev Dis Primers. 2019, 5:58. 10.1038\/s41572-019-0105-0","journal-title":"Nat Rev Dis Primers"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S451346","article-title":"Reasons, efficacy and safety of switching to dolutegravir-based regimens among virologically suppressed PLWH: a retrospective cohort study of 96 weeks","volume":"17","author":"Deng M","year":"2024","unstructured":"Deng M, Chen N, Lao X, Wang X, Fu J, Xing L, Zhao H. Reasons, efficacy and safety of switching to dolutegravir-based regimens among virologically suppressed PLWH: a retrospective cohort study of 96 weeks. Infect Drug Resist. 2024, 17:1571-82. 10.2147\/IDR.S451346","journal-title":"Infect Drug Resist"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13489","article-title":"Efficacy and safety of dolutegravir\/rilpivirine in real-world clinical practice. GeSIDA study 1119","volume":"24","author":"Palacios R","year":"2023","unstructured":"Palacios R, G\u00f3mez-Ayerbe C, Casado JL, et al.. Efficacy and safety of dolutegravir\/rilpivirine in real-world clinical practice. GeSIDA study 1119. HIV Med. 2023, 24:933-7. 10.1111\/hiv.13489","journal-title":"HIV Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-13504-3","article-title":"Drug induced liver injury in HIV patients on dolutegravir based antiretroviral therapy regimens in Wolaita Sodo comprehensive specialized hospital","volume":"15","author":"Abraham F","year":"2025","unstructured":"Abraham F, Toma A, Balcha T, Tigabu BM. Drug induced liver injury in HIV patients on dolutegravir based antiretroviral therapy regimens in Wolaita Sodo comprehensive specialized hospital. Sci Rep. 2025, 15:28013. 10.1038\/s41598-025-13504-3","journal-title":"Sci Rep"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.56424","article-title":"Adverse drug reactions and prescription patterns of antiretroviral drugs: a longitudinal observational study from a tertiary care hospital in western India","volume":"16","author":"Sekar VD","year":"2024","unstructured":"Sekar VD, Joshi K, Bhide S, et al.. Adverse drug reactions and prescription patterns of antiretroviral drugs: a longitudinal observational study from a tertiary care hospital in western India. Cureus. 2024, 16:e56424. 10.7759\/cureus.56424","journal-title":"Cureus"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3390\/ph18070955","article-title":"HIV infection and antiretroviral therapy impair liver function in people living with HIV: systematic review and meta-analysis","volume":"18","author":"Strauss KE","year":"2025","unstructured":"Strauss KE, Phoswa WN, Hanser S, Mokgalaboni K. HIV infection and antiretroviral therapy impair liver function in people living with HIV: systematic review and meta-analysis. Pharmaceuticals (Basel). 2025, 18:10.3390\/ph18070955","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa259","article-title":"The integrase inhibitors dolutegravir and raltegravir exert proadipogenic and profibrotic effects and induce insulin resistance in human\/simian adipose tissue and human adipocytes","volume":"71","author":"Gorwood J","year":"2020","unstructured":"Gorwood J, Bourgeois C, Pourcher V, et al.. The integrase inhibitors dolutegravir and raltegravir exert proadipogenic and profibrotic effects and induce insulin resistance in human\/simian adipose tissue and human adipocytes. Clin Infect Dis. 2020, 71:e549-60. 10.1093\/cid\/ciaa259","journal-title":"Clin Infect Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/509357-longitudinal-hepatic-and-metabolic-trajectories-following-dolutegravir-initiation-in-antiretroviral-therapy-art-nave-people-living-with-hiv-a-prospective-cohort-study-from-south-india","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T09:50:32Z","timestamp":1783763432000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/509357-longitudinal-hepatic-and-metabolic-trajectories-following-dolutegravir-initiation-in-antiretroviral-therapy-art-nave-people-living-with-hiv-a-prospective-cohort-study-from-south-india"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,11]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.112448","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,11]]}}}